Drugs / Triamcinolone
Triamcinolone
also known as
Triamcinolone acetate · Kenalog · triamcinolone acetonide · Kenacort · Aristocort · TAC · Formulated Triamcinolone · FX006 · +16 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ARISTOCORT | — | 1957-12-03 | fda.gov ↗ |
Trials 94 · started per year
today
US approved 1957
1
1
1
2
4
4
2
4
2
1
5
3
1
6
1
5
5
6
2
9
3
6
6
1
3
8
19561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04126824 | Jan 2022 → Aug 2026 overdue | adenomyosis, uterine benign neoplasm | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03729310 | Mar → May 2020 | chronic rhinosinusitis | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 13 trials | ||||||
| Phase 1 | NCT06362226 | Jun 2026 | disorder of orbital region | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00211419 | — | age-related macular degeneration | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00893854 | — | cystoid macular edema, uveitis | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01222871 | Jul 2010 → Jul 2012 | nasal cavity polyp | Steward St. Elizabeth's Medical Center of Boston, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00849537 | Apr 2008 → Apr 2009 | diabetic retinopathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT06840561 | Nov 2021 → Dec 2024 | esophageal cancer | Sun Yat-sen University Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03115567 | Feb 2017 → Apr 2020 | acneiform dermatitis | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00701233 | Jun 2012 → Oct 2018 | carpal tunnel syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT00597766 | Dec 2007 → Feb 2012 | arthropathy | MetroHealth Medical Center | Completed | Missed primary |
| Phase 2 | NCT00370630 | Aug 2006 → Feb 2007 | retinal vascular disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00370266 | Feb 2003 → Oct 2007 | occlusion of tributary of retinal vein | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00021294 | May 2001 → Jun 2002 | precancerous condition, skin cancer | University of Arizona | Completed | No outcome recorded |
| Phase 2/37 trials · 2 met primary · 1 missed | ||||||
| Phase 2/3 | NCT07445191 | Mar → Jun 2026 overdue | temporomandibular joint disorder | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT02191748 | Sep 2014 → Jan 2018 | vitiligo | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2/3 | NCT00717652 | Jul 2008 | hyperpigmentation of the skin | Azidus Brasil | Suspended | No outcome recorded |
| Phase 2/3 | NCT00930189 | Apr 2006 | choroidal neovascularization | Asociación para Evitar la Ceguera en México | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00148330 | May 2005 → Jul 2008 | diabetic macular edema | University of Sydney | Completed | Met primary |
| Phase 2/3 | NCT00148265 | Apr 2005 → May 2009 | diabetic macular edema | University of Sydney | Completed | Missed primary |
| Phase 2/3 | NCT00167518 | Mar 2002 → Apr 2005 | diabetic macular edema | University of Sydney | Completed | Met primary |
| Phase 312 trials · 1 met primary | ||||||
| Phase 3 | NCT07228104 | May 2026 → Jan 2031 expected | idiopathic subglottic stenosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT06288685 | Oct 2023 → Jan 2024 | arthropathy | Police General Hospital, Thailand | Completed | No outcome recorded |
| Phase 3 | NCT03958344 | Jan 2022 → Jun 2024 | orbital pseudotumor | Iran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT04094298 | Jul 2019 → Oct 2024 overdue | rotator cuff syndrome, shoulder impingement syndrome, tendinitis | Northwell Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03616340 | Aug 2018 → Aug 2019 | osteoarthritis, knee, rotator cuff syndrome, shoulder impingement syndrome | OSF Healthcare System | Unknown | No outcome recorded |
| Phase 3 | NCT03317015 | Nov 2016 → Jul 2017 | allergic rhinitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02556424 | Jan 2016 → Feb 2021 | macular retinal edema | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01318590 | Nov 2011 → Jun 2019 | chronic pancreatitis | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 3 | NCT00997191 | Oct 2009 → Nov 2011 | diabetic macular edema | University of Sao Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00658736 | Mar 2008 → Jan 2011 | chronic pancreatitis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00806169 | Apr 2006 → Oct 2008 | diabetic retinopathy, macular retinal edema | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00370422 | Nov 2005 → Sep 2006 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | Met primary |
| Phase 432 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07494136 | May 2026 → May 2027 expected | radiculopathy, sciatica | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07276802 | Apr → Dec 2026 expected | cataract | Research Insight LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07508098 | Jul 2025 → Jan 2026 | hyperpigmentation of the skin | Pak Emirates Military Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05364099 | Nov 2023 → Jan 2024 | chronic pain syndrome | University of Miami | Withdrawn | No outcome recorded |
| Phase 4 | NCT05845125 | May 2023 → May 2024 | frozen shoulder | Claire Bourgeois | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT05997238 | Apr 2023 → Feb 2024 | osteoarthritis, knee | Peking University Third Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05844930 | Jan 2023 → Feb 2025 | frozen shoulder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04524897 | Dec 2020 → Oct 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04687930 | Dec 2020 → Feb 2021 | juvenile idiopathic arthritis, osteoarthritis, knee | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT04278833 | Sep 2020 → May 2021 | disease of the tendon, osteoarthritis, shoulder impingement syndrome | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05220527 | Aug 2020 → Jul 2022 | osteoarthritis, knee | Taipei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04361513 | Apr → Jul 2020 | arthropathy | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT05660694 | Jan 2020 → Sep 2021 | neoplasm, oral submucous fibrosis | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03797872 | Apr 2019 → Jul 2020 | psoriatic arthritis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT03982862 | Jul 2018 → Jun 2019 | keloid | Kaohsiung Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03901768 | Apr 2018 → Jan 2020 | — | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT03361176 | Mar → Oct 2018 | obesity disorder | Goldman, Butterwick, Fitzpatrick and Groff | Completed | No outcome recorded |
| Phase 4 | NCT03407027 | Nov 2017 → Apr 2019 | — | Hospital de Braga | Unknown | No outcome recorded |
| Phase 4 | NCT03777891 | Jun 2017 | reactive cutaneous fibrous lesion | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02949466 | Oct 2016 → Jul 2017 | — | Taipei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02748395 | May → Dec 2016 | anterior cutaneous nerve entrapment syndrome | Temple University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02680301 | Mar 2016 → Mar 2017 | atopic eczema | Seton Healthcare Family | Completed | No outcome recorded |
| Phase 4 | NCT02317276 | Dec 2014 → Apr 2017 | atopic eczema | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01995045 | Jul 2012 → Dec 2015 | proliferative vitreoretinopathy, retinal detachment, retinoschisis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01599273 | May 2012 → Aug 2014 | disease of orbital part of eye adnexa | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01420471 | Sep 2011 → May 2012 | sinusitis | St. Paul's Hospital, Canada | Completed | No outcome recorded |
| Phase 4 | NCT01898806 | Sep 2011 → Jan 2018 | alopecia areata | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT01335321 | Mar → Nov 2011 | osteoarthritis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00826462 | Mar 2009 → Jun 2013 | epicondylitis | University of Oslo | Completed | Mixed |
| Phase 4 | NCT02049879 | Nov 2008 → Aug 2012 | osteoarthritis, knee | Laval University | Completed | No outcome recorded |
| Phase 4 | NCT00566761 | Jun 2007 | central retinal vein occlusion, macular retinal edema | Asociación para Evitar la Ceguera en México | Terminated | No outcome recorded |
| Phase not applicable29 trials · 1 met primary · 1 missed | ||||||
| — | NCT07603921 | Sep 2026 → May 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07591233 | Jun 2026 → Mar 2027 expected | gallbladder disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07828574 | Jan 2025 → Jun 2026 overdue | pudendal neuralgia | Irkutsk State Medical University | Active not recruiting | No outcome recorded |
| — | NCT07817433 | Jan 2025 → Feb 2026 | disease of the tendon | Gaziler Physical Medicine and Rehabilitation Education and Research Hospital | Completed | No outcome recorded |
| — | NCT05526898 | Oct 2024 → Dec 2025 | osteoarthritis, knee | Syntr Health Technologies, Inc. | Unknown | No outcome recorded |
| — | NCT06004882 | Aug 2023 → Jan 2027 expected | chronic pain syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT06170593 | Nov 2022 → Jan 2023 | acne | ACOM Labs | Completed | No outcome recorded |
| — | NCT05248139 | Oct 2022 → Feb 2023 | cataract, ocular hypertension | Visualiza | Unknown | No outcome recorded |
| — | NCT05738759 | May 2022 → Jul 2024 | lumbar disk disease | Queen Savang Vadhana Memorial Hospital, Thailand | Unknown | No outcome recorded |
| — | NCT06955455 | Jan 2022 → Oct 2024 | Bell's palsy | Tishreen University Hospital | Completed | No outcome recorded |
| — | NCT05381558 | Apr 2021 → Sep 2022 | flatfoot | Assiut University | Unknown | No outcome recorded |
| — | NCT04014244 | Mar 2021 → Mar 2022 | carpal tunnel syndrome | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT06228911 | Jan 2020 → Sep 2023 | osteoarthritis, knee, type 2 diabetes mellitus | Syrian Private University | Completed | No outcome recorded |
| — | NCT04165512 | Jan → Mar 2020 | lymphedema | Marmara University | Unknown | No outcome recorded |
| — | NCT03678038 | Sep 2018 → Jan 2021 | frozen shoulder | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT03871465 | Aug 2018 → Jul 2020 | bursitis, shoulder impingement syndrome | Shin Kong Wu Ho-Su Memorial Hospital | Completed | No outcome recorded |
| — | NCT04235478 | Dec 2017 → Feb 2020 | cervical disk degenerative disorder, neuropathy, painful | Marmara University | Unknown | No outcome recorded |
| — | NCT03039608 | Feb 2017 → Jul 2018 | — | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| — | NCT02704507 | Jun 2015 → Jan 2016 | acne | Carilion Clinic | Unknown | No outcome recorded |
| — | NCT02399800 | Dec 2014 → Feb 2018 | chronic pancreatitis | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02653963 | Sep 2014 → Apr 2016 | glaucoma | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT02702206 | Aug 2014 → Oct 2016 | bursitis | Shin Kong Wu Ho-Su Memorial Hospital | Completed | Met primary |
| — | NCT02577991 | Feb 2014 → Jun 2017 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT06493656 | Dec 2013 → Nov 2015 | frozen shoulder | Chuncheon Sacred Heart Hospital | Completed | No outcome recorded |
| — | NCT01280214 | Feb 2011 → Feb 2013 | thyroid gland disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| — | NCT00478764 | Mar 2006 → Apr 2007 | cataract | Dean Health System | Completed | No outcome recorded |
| — | NCT00640575 | Mar 2005 → Oct 2006 | rotator cuff syndrome | Ullevaal University Hospital | Completed | Missed primary |
| — | NCT00441662 | Nov 2004 → May 2007 | melanoma | Wills Eye | Completed | No outcome recorded |
| — | NCT00668239 | Sep 2004 → Apr 2006 | diabetic macular edema | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Comparator or background therapy108 trials | ||||||
| Phase 0 | NCT06032039 Comparator | Oct 2023 → Oct 2024 | osteoarthritis, knee | The University of The West Indies | Unknown | No outcome recorded |
| Phase 0 | NCT05349448 Comparator | Mar → Nov 2022 | neuropathy, painful | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT04036188 Background | Oct 2019 → Dec 2026 expected | psoriasis | Wright State University | Recruiting | No outcome recorded |
| Phase 1 | NCT06504160 Background | May 2025 → Dec 2026 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT04929951 Comparator | Jul 2022 → Dec 2027 expected | osteoarthritis | Stanford University | Recruiting | No outcome recorded |
| Show all 108 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Harrow Inc | Regulatory Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication harrow.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application |
| 2025-10-01 | Alembic Pharmaceuticals Ltd. | Regulatory 18th October, 2025 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials). |
| 2025-03-24 | Harrow Inc | Regulatory Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL harrow.com ↗
CMS will now separately reimburse TRIESENCE at the Average Sales Price (ASP) plus 6% in both ASC and HOPD settings. |
| 2023-07-30 | Pharco Pharmaceuticals | Regulatory The Selection and Use of Essential Medicines 2023 pharco.org ↗
The Expert Committee recommended the inclusion of triamcinolone hexacetonide on the complementary list of the EML and EMLc for use in the treatment of juvenile idiopathic arthritis. |
| 2015-04-16 | Perrigo Company | Regulatory Perrigo Announces The Launch Of A Generic Version Of Kenalog® Nasal Spray perrigo.com ↗
today announced that it has received final Federal Drug Administration approval for Triamcinolone Acetonide Topical Aerosol, the generic version of Sun Pharma's Kenalog® nasal spray. |
All press releases naming this drug 10 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 204 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triamcinolone | “Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound...” NCT05977985 ↗186“The cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.” NCT05738759 ↗ “Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint” NCT01920373 ↗ “Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.” NCT06653985 ↗ “EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis” NCT01318590 ↗ “Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .” NCT03704584 ↗ “8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.” NCT00928564 ↗ “Advanced Touhy needle delivery of 80 mg triamcinolone and 1500 IU hyaluronidase into the epidural space to target inflammation and adhesions” NCT07370233 ↗ “The proposed study will compare the efficacy of Triamcinolone versus Ketorolac for intra-articular injection of the knee and shoulder” NCT03616340 ↗ “1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)” NCT04143165 ↗ “GON block using 3-5 mL of local anesthetic, optionally combined with 20-40 mg triamcinolone ( Bilaterally )” NCT07512219 ↗ |
| Known as | Aristocort | “Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).” NCT02108496 ↗1“Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).” NCT02136901 ↗ |
| Known as | Formulated Triamcinolone | “Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate” NCT05464953 ↗ |
| Known as | FX006 | “The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator...” NCT04094298 ↗ |
| Known as | IVT | “To evaluate the effect of three intravitreal injections of bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractory...” PMID 17917738 ↗ Oct 2007 |
| Known as | Kenacort | “20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints.” NCT05852808 ↗ |
| Known as | Kenacort - T (triamcinolone) | “Kenacort - T (triamcinolone)” NCT00826462 ↗ |
| Known as | Kenacort Bristol Myers Squip | “1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)” NCT04143165 ↗ |
| Known as | Kenacort-A | “Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.” NCT05271058 ↗ |
| Known as | Kenalog | “Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.” NCT06653985 ↗7“Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).” NCT02136901 ↗ “Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).” NCT02108496 ↗ “A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.” NCT02049879 ↗ “a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination” NCT06362226 ↗ “Intraoperative delivery of medication, Kenalog (Triamcinolone)” NCT05248139 ↗ “Kenalog (triamcinolone; corticosteroid injection)” NCT00398866 ↗ “Kenalog” NCT03641508 ↗ |
| Known as | Kenalog = Triamcinolone | “Kenalog = Triamcinolone” NCT00597766 ↗ |
| Known as | Lederspan, Meda AB, Solna, Sweden (Triamcinolone) | “Lederspan, Meda AB, Solna, Sweden (Triamcinolone)” NCT00757016 ↗ |
| Known as | Shincort | “Triamcinolone (Shincort) injection to rotator interval” NCT03678038 ↗ |
| Known as | TA-ER | “The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator...” NCT04094298 ↗ |
| Known as | TAC | “DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID” NCT03011892 ↗1“Triamcinolone (TAC) 0.1% cream” NCT06994520 ↗ |
| Known as | Triamcenolone in orabase | “Triamcenolone in orabase” NCT03877679 ↗ |
| Known as | Triamcinolone (Kenalog) | “Triamcinolone (Kenalog)” NCT01830699 ↗ |
| Known as | Triamcinolone acetate | “The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator...” NCT04094298 ↗12“Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment” NCT06498180 ↗ “Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance).” NCT06754033 ↗ “4.7% N-acetylcysteine, 2% Hydroquinone and 0.1 % triamcinolone acetate twice daily for 8 weeks” NCT07508098 ↗ |
| Known as | triamcinolone acetonide | “Triamcinolone acetonide is a synthetic corticosteroid with a preventive effect on collagen synthesis, fibrosis, and chronic cicatrization that has been used for many years,...” NCT04524897 ↗3“Perineural injection of articaine hydrochloride with epinephrine (20 mg/mL + 0.005 mg/mL, 5 mL) combined with triamcinolone acetonide (40 mg in 1 mL), diluted with 0.9% saline...” NCT07828574 ↗ “A few years ago, however, only triamcinolone acetonide was available to ophthalmologists.” PMID 32041669 ↗ Feb 2020 “Triamcinolone Acetonide 40mg/mL” NCT03382821 ↗ |
| Known as | Triancil | “A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)” NCT01335321 ↗ |
| Known as | Triesence | “subconjunctival injection of triamcinolone 40mg/mL (Triesence) at the end of surgery” NCT07276802 ↗ |
| Known as | trigon depot | “blind injection of 40 mg of triamcinolone (trigon depot ®)” NCT03046108 ↗ |
| Known as | Volon A | “The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline.” NCT00682539 ↗ |
| Known as | Volon A10 | “one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)” NCT00731289 ↗ |
| Known as | XRG5029 | “triamcinolone XRG5029” NCT03317015 ↗ |
| Action | Inhibit | “The rationale for the use of corticosteroids in temporomandibular joint therapy is that they inhibit prostaglandin synthesis and decrease the activity of collagenase and other...” NCT01920373 ↗ |
| Modality | Other / unclassified | “Corticosteroid: Triamcinolone” NCT00623766 ↗ |
| Route | Topical | “Patients receive eflornithine (DFMO) topically and triamcinolone topically to forearms once daily.” NCT00021294 ↗ |